Pioglitazone reduces neointima volume after coronary stent implantation: A randomized, placebo-controlled, double-blind trial in nondiabetic patients

Circulation

Volumn 112, Issue 18, 2005, Pages 2792-2798

  Marx, Nikolaus ^a   Wöhrle, Jochen ^a   Nusser, Thorsten ^a   Walcher, Daniel ^a   Rinker, Angelika ^a   Hombach, Vinzenz ^a   Koenig, Wolfgang ^a   Höher, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Coronary disease; Diabetes mellitus; Intima; Stents; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ADULT; ADVENTITIA; AGED; ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INTIMA; INTRAVASCULAR ULTRASOUND; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BIOLOGICAL MARKERS; CORONARY DISEASE; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 27844538450     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.535484     Document Type: Article

References (29)

1. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JU Garcia E, Calabuig J. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol, 1999;34:1498-1506.
2. Mudra H, di Mario C, de Jaegere P, Figulla HR, Macaya C, Zahn R, Wennerblom B, Rutsch W, Voudris V, Regar E, Henneke KH, Schachinger V, Zeiher A. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation. 2001;104:1343-1349.
3. Bittl JA. Advances in coronary angioplasty. N Engl J Med. 1996;335:1290-1302.
4. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-1671.
5. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714-1719.
6. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: EXCITE Trial Investigators: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000;342:1316-1324.
7. Wohrle J, Hoher M, Nusser T, Hombach V, Kochs M. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can J Cardiol. 2003;19:495-500.
8. Schoonjans K, Auwerx J. Thiazoledinediones: an update. Lancet. 2000;355:1008-1010.
9. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
10. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPAR-γ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
11. Goetze S, Xi XP, Kawano H, Gotlibowski T, Reck E, Hsueh WA, Law RE. PPAR-γ ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol. 1999;33:798-806.
12. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator activated receptor-γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097-1103.
13. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest. 1996;98:1897-1905.
14. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
15. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, Akasaka T, Yoshida K. Impact of troglitazone on coronary stent implantation using small stems in patients with type 2 diabetes mellitus. Am J Cardiol. 2002;89:318-322.
16. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003;146:E5.
17. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654-2660.
18. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. The antidiabetic PPAR-γ activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:282-288.
19. Koning G, Dijkstra J, von Birgelen C, Tuinenburg JC, Brunette J, Tardif JC, Oemrawsingh PW, Sieling C, Melsa S, Reiber JH. Advanced contour detection for three-dimensional intracoronary ultrasound: a validation: in vitro and in vivo. Int J Cardiovasc Imaging. 2002;18:235-248.
20. Hoher M, Wohrle J, Wohlfrom M, Kamenz J, Nusser T, Grebe OC, Hanke H, Kochs M, Reske SN, Hombach V, Kotzerke J. Intracoronary β-irradiation with a rhenium-188-filled balloon catheter: a randomized trial in patients with de novo and restenotic lesions. Circulation. 2003;107:3022-3027.
21. Wohrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, Hombach V, Hoher M. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardtal infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840-1843.
22. Hoffmann R, Mintz GS. Coronary in-stent restenosis: predictors, treatment and prevention. Eur Heart J. 2000;21:1739-1749.
23. Cominacini L, Young MM, Capriati A, Garbin U, Fratta-Pasini A, Campagnola M, Davoli A, Rigoni A, Contessi GB, Lo Cascio V. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 1997;40:1211-1218.
24. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, Al-Omran M, Chemg WJ, Li RK, Stanford WL, Verma S. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation. 2004;109:1392-1400.
25. Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol. 2004;64:151-156.
26. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362-365.
27. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
28. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370-2376.
29. Stone GW, Ellis SG, O'Shaughnessy CD, Statler L, Martin S, McGarry T, Turco M, Kereiakes DJ, Jacobs WC, Russell ME. A prospective, multicenter randomized trial of the paclitaxel-eluting stent versus vascular brachytherapy in patients with coronary in-stent restenosis: the TAXUS-V ISR Trial. J Am Coll Cardiol. 2005;45(suppl A):83A.